Weston C, Rao U
Department of Cardiology, Singleton Hospital, Swansea, UK.
Int J Clin Pract. 2003 Dec;57(10):898-905.
Platelets play a key role in the pathogenesis of atherothrombotic conditions, e.g. acute coronary syndromes, cerebrovascular and peripheral vascular events. Antiplatelet agents interfere with platelet activation and aggregation and, as such, would be expected to modify the natural history of cardiovascular disease. In this review we explore the evidence to support the use of such drugs, singly or in combination, in a variety of situations characterised by thrombosis and summarise some of the concerns inherent in their use.
血小板在动脉粥样硬化血栓形成疾病（如急性冠脉综合征、脑血管和外周血管事件）的发病机制中起关键作用。抗血小板药物可干扰血小板的激活和聚集，因此有望改变心血管疾病的自然病程。在本综述中，我们探讨了支持此类药物单独或联合用于各种血栓形成相关情况的证据，并总结了其使用中存在的一些固有问题。
